PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) traded down 0.1% during mid-day trading on Friday . The stock traded as low as $0.5310 and last traded at $0.5402. Approximately 57,214 shares were traded during trading, an increase of 548% from the average daily volume of 8,831 shares. The stock had previously closed at $0.5405.
PharmaCyte Biotech Stock Down 4.7%
The business’s 50 day moving average is $0.64 and its 200-day moving average is $0.69.
PharmaCyte Biotech Company Profile
PharmaCyte Biotech is a clinical‐stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose‐based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.
In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.
Recommended Stories
- Five stocks we like better than PharmaCyte Biotech
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
